Applied DNA Sciences (APDN) and Alphazyme (MRVI) announced the successful conclusion of the companies’ previously announced Linea RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA’s anticipated near-term demand for critical starting material for mRNA production.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APDN:
- Applied DNA Sciences partners with GenXys Health Care Systems
- Applied DNA Sciences receives approval for TR8 PGx teging service
- Applied DNA Sciences price target lowered to $1.50 from $7 at H.C. Wainwright
- Applied DNA announces notice of allowance for U.S. patent covering Linea RNAP
- Applied DNA Sciences’ $12M Securities Offering and Agreement